Cabaletta Bio Inc (CABA)

Jan 6, 2025, 2:28 PM EST - 11 days ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 3 months ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 4 months ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 28, 2024, 8:00 AM EDT - 5 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 8, 2024, 7:00 AM EDT - 5 months ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 7 months ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 7 months ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 7 months ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 8 months ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 8 months ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 10 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 11 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 1 year ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 1 year ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 1 year ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 1 year ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 1 year ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 1 year ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 1 year ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 1 year ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 19, 2023, 4:56 AM EDT - 1 year ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

May 31, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 22, 2023, 4:30 PM EDT - 1 year ago

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 21, 2023, 8:20 AM EDT - 1 year ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CYH EXAS MRNA NVAX ORGO PFE RARE

May 17, 2023, 10:16 PM EDT - 1 year ago

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 17, 2023, 4:01 PM EDT - 1 year ago

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 16, 2023, 7:00 AM EDT - 1 year ago

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 11, 2023, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 4:35 PM EDT - 1 year ago

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

Apr 27, 2023, 4:49 PM EDT - 1 year ago

Cabaletta Bio: Speculative Biotech With Opportunity

Apr 25, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Apr 13, 2023, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

Mar 31, 2023, 7:00 AM EDT - 1 year ago

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus

Mar 16, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 28, 2023, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

Jan 25, 2023, 6:29 AM EST - 2 years ago

Cabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)

Jan 5, 2023, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 22, 2022, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference

Nov 10, 2022, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 20, 2022, 5:56 PM EDT - 2 years ago

5 Stocks Insiders Are Buying in October

CCNE MBIN PLAY

Oct 6, 2022, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

Sep 10, 2022, 7:00 AM EDT - 2 years ago

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

Aug 29, 2022, 1:58 PM EDT - 2 years ago

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

Aug 11, 2022, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update